Neurotechnology startup Subsense, Inc. has emerged from stealth mode, announcing a $17 million seed funding round led by Golden Falcon Capital to develop its innovative non-surgical brain-computer interface (BCI) technology. The company's approach utilizes nanoparticles to create a bidirectional connection between the brain and external devices, offering a potential breakthrough in treating neurological conditions.

The company was founded by Tetiana Aleksandrova, a neurotechnology entrepreneur focused on brain health innovation, and Artem Sokolov, a serial entrepreneur known for early investments in successful ventures including Asana, SoFi, and Coursera. Addressing the technology's potential, CEO Aleksandrova stated, "Brain-computer interfacing promises to unlock limitless human potential, but innovation has been held back by a lack of effective non-surgical approaches. By delivering nanoparticles that bind with receptors in the brain, Subsense can achieve more extensive connectivity with a far gentler approach."

Subsense has established strategic collaborations with leading research institutions, including UC Santa Cruz and ETH Zurich, to accelerate the development and validation of its technology. The company's initial therapeutic focus targets major neurological conditions including Parkinson's disease, Alzheimer's disease, epilepsy, depression, stroke, and chronic pain.

Beyond immediate therapeutic applications, Subsense is exploring broader applications of its technology. These include sensorimotor recovery for restoring vision, hearing, and movement capabilities, inner speech decoding for thought-to-text translation, and AI integration for connecting human brains with artificial neural networks. Additional development areas encompass external memory systems for human memory backup and extension, mental health regulation for emotion and mood control, and appetite management through hunger signal modulation.

Click here for the original news story.